Novo Nordisk: A Long-Term Owner's Perspective

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?7/10

  A

  The ceiling is very high. In substance, it is both expanding an existing giant pie and turning it into a new market. The caveat is that Novo Nordisk no longer has this pie to itself.

  Start with the size of the pie. The demand-side runway is beyond dispute: WHO data show that in 2022 about 1 in 8 people worldwide were living with obesity, and adult obesity had more than doubled since 1990 (WHO Obesity and overweight fact sheet); the International Diabetes Federation, IDF, estimates that in 2024 there were 589 million adults aged 20–79 with diabetes globally, rising to 853 million by 2050 (IDF Diabetes Atlas 2025); the U.S. CDC reports about 40.10 million people with diabetes in the U.S. in 2023 and about 115.2 million adults with prediabetes (CDC National Diabetes Statistics Report). The report's use of these three sets of figures matches the primary sources, and its conclusion is also right: long-term demand is not the issue.

  The key question is whether this is expanding an existing pie or creating a new market. The answer is both. Diabetes treatment is a mature market that has existed for more than a century, and Novo Nordisk is an established player. That part is about taking share in an existing pie and using GLP-1 to upgrade the standard of care. Obesity, as a market for systematic treatment with prescription drugs, barely existed before this generation of GLP-1 drugs such as Wegovy/Ozempic. That is the true creation of a new market: hundreds of millions of people with obesity who previously relied mainly on lifestyle intervention, with almost no effective medicines available, have for the first time become an addressable market covered by prescription drugs. The report is directionally correct in describing future growth as still mainly coming from expansion of the GLP-1 market.

  But any statement that the ceiling is high needs one sober qualification: the share of that ceiling captured by Novo Nordisk is being eroded. It is the global branded-volume share leader in obesity/diabetes. Under its 2025 annual-report definition, branded volume market share was about 59.6% (Novo Nordisk Annual Report 2025, Financial performance). The report's figure of about 55% share in weekly injectable GLP-1 is a narrower sub-segment definition from company investor materials; the two are not inconsistent. The problem is that Lilly is expanding faster under the same ceiling: in Q1 2026, Lilly's Mounjaro and Zepbound generated combined revenue of about USD 12.82 billion, with total revenue up 56% year over year (Lilly Q1 2026 press release), and some market measures already put Lilly's GLP-1 share at around 60%.

  So, for Baillie Gifford's question on how high the ceiling is, the honest conclusion is this: the industry ceiling is extremely high and still rising, both expanding an existing pie and opening a new obesity market, so the business has a real long runway. But even a very high ceiling only becomes value for Novo Nordisk if it can still take enough share, and at the right price, in a market that is turning into an intense duopoly fight. That is the core tension behind the report's Watch rating rather than Buy.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?3/10

  A

  Probably not. Doubling revenue over the next five years, or about 15% annualized, is a high bar for Novo Nordisk today. The current growth structure is volume up, price down, and netting effects materially drag the growth rate. That is the opposite of Baillie Gifford's preferred pattern of rising volume, rising price, and accelerating growth.

  First set the starting point. Novo Nordisk's 2025 revenue was DKK 309.064 billion (Novo Nordisk Annual Report 2025, Financial performance), exactly in line with the primary source cited in the report. A five-year doubling would require about DKK 618.0 billion of revenue by 2030, or about 14.9% annualized growth. Historically it could do that: the report gives a 2019–2025 revenue CAGR of about 16.8%. The issue is that this was the window when the GLP-1 narrative was strongest and pricing power was at its peak. Today's trend line has already turned.

  The strongest counterevidence comes from the company's own current disclosures. In Q1 2026, adjusted sales excluding the one-off 340B provision reversal fell 4% year over year at constant exchange rates, CER, and adjusted operating profit fell 6% (Novo Nordisk Q1 2026 Form 6-K; see also GlobeNewswire: Novo Nordisk's Q1 2026 adjusted operating profit of DKK 32,858 million). More damaging is the full-year 2026 guidance: adjusted sales growth is guided at -4% to -12%, CER. For a company guiding to negative full-year growth, a five-year revenue doubling is arithmetically very demanding. It requires a strong reversal from 2027 onward.

  Now break down the drivers: volume, price, and new business.

  • Volume: still a positive contributor and the only hard support. In Q1 2026, injectable Wegovy revenue rose 12% year over year to DKK 18,235 million, and GLP-1 volumes continued to expand across regions (Novo Nordisk Q1 2026 Form 6-K).
  • Price: clearly a negative contributor. The report repeatedly cites the company's 2026 guidance language on lower realised prices, the U.S. gross-to-net system, Most Favoured Nations policy, 340B items, and the loss of exclusivity for semaglutide in some international markets. Ozempic sales fell 8% in the quarter. A peer comparison is useful: Lilly's Q1 2026 global realised prices fell 13% year over year, with the U.S. down 7% and international down 25% (Lilly Q1 2026 press release). The whole category is trading price for volume.
  • New business: oral Wegovy is the real new increment. It contributed DKK 2,256 million in its first quarter and about 1.30 million prescriptions (Novo Nordisk Q1 2026 Form 6-K), and is set for broader international rollout in the second half. This is the most likely line to support growth, but its unit price is lower, so while it expands revenue it will further dilute the overall unit price.

  Overall judgment: whether Novo Nordisk can double revenue in five years depends on whether rapid volume expansion can outweigh sustained price pressure. With Lilly attacking across the board, payers applying systematic price pressure, and the company itself guiding to negative growth, my honest conclusion is that a doubling is the upper end of an optimistic scenario, not the base case. The report's view that future growth depends more on price-system and cash-flow repair than on simple volume growth is consistent with this conclusion. Today's Novo Nordisk looks more like a high-quality mature pharmaceutical company trying to sustain mid-single-digit to low-double-digit growth through volume than a Baillie-style accelerating growth stock that can easily double in five years.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this second curve exist today?5/10

  A

  The second curve half exists today. Oral GLP-1 is already launched and generating real volume, making it the closest successor. But the next generation of multi-target or new-mechanism obesity pipelines has not yet delivered, and the more distant baton is still on the way. Overall, Novo Nordisk's succession lineup is thinner than Lilly's, which is the company's biggest current growth uncertainty.

  First define what counts as taking over. Novo Nordisk's revenue engine today remains highly concentrated in the semaglutide family, Ozempic and injectable Wegovy. The report also acknowledges in its open questions that the company's advantage still centers mainly on the semaglutide family. A real second curve should therefore be something new that can carry growth independently after semaglutide growth slows, or after exclusivity is lost in some markets.

  The successor that already exists and is delivering: oral Wegovy, the oral semaglutide obesity formulation. This is the most concrete second curve today. It launched in the U.S. in January 2026 and contributed DKK 2,256 million in revenue in Q1, with about 1.30 million prescriptions, roughly twice analyst expectations. It will also roll out across international markets in the second half (Novo Nordisk Q1 2026 Form 6-K). It extends GLP-1 from weekly injection to daily oral dosing and reaches a large population that resists injections. In that sense, it is a genuine new dosage-form market. The report is right to list it as a key tracking metric, namely oral Wegovy's volume, price, and gross-margin structure. It is indeed taking the baton, but with one hard constraint: the unit price is lower and the gross-margin structure still needs observation, so it clearly expands volume while its ability to expand profit remains uncertain.

  The more distant curve that is on the way but has not yet delivered: next-generation obesity pipelines and business development, BD. The report repeatedly notes that the company is in an intensive capacity-expansion and BD cycle. In 2025, intangible-asset investments reached DKK 29.973 billion, mainly related to business-development activity, especially the Akero-related transaction (Novo Nordisk Annual Report 2025, Financial performance). This shows that management is indeed placing bets beyond the current product set, including directions such as MASH/metabolic liver disease. But these remain investment-stage assets with no visible revenue yet. They are second curves that are not visible today. The report is cautious and honest in listing whether next-generation pipelines and BD spending can generate high returns as a falsification condition.

  Compare it with the rival to understand the relative depth of this curve. Baillie Gifford's question, whether the second curve exists today, has to be assessed in a competitive context. Lilly's succession lineup is clearly thicker: beyond the rapid growth of Mounjaro/Zepbound, its oral GLP-1 Foundayo, orforglipron, has received FDA approval and launched in the U.S. in the second quarter as an oral obesity drug that can be taken at any time, without food or water restrictions (FDA approves Lilly's Foundayo (orforglipron)). In other words, Novo Nordisk's oral second curve has just started running, while a comparable rival curve is arriving at the same time. Before the second curve has created distance, it is already in head-to-head competition.

  The honest conclusion: Novo Nordisk does have one second curve today, oral Wegovy, and it is already contributing real money. That is better than simply overexploiting existing products. But it dilutes unit price, directly faces Lilly's comparable product, and the more distant third curve, next-generation mechanisms plus BD, has not yet delivered. From a Baillie Gifford perspective, this is a company where a successor is already on the field, but whether it can outrun the rival with the baton remains unproven. Continuity of growth is an honest question, not an answered fact.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  The core moat is a combination of brand, clinical evidence, scaled biologics manufacturing, global regulatory channels, and long-term foundation control. It remains wide. But over the next three to five years the direction is stable to narrowing, rather than continuing to widen. This is one of the report's most restrained and important judgments.

  First look at what the moat consists of. The report breaks it into five pieces, each of which holds up:

  • Brand and clinical trust: Ozempic and Wegovy are among the world's most recognized GLP-1 brands, backed by years of large-scale clinical and real-world evidence.
  • Scale and manufacturing: in its Q1 2026 investor materials, the company says it is the world's largest insulin and GLP-1 manufacturer. High-volume biologics API platforms, continuous production processes, high installed capacity, and in-house development and manufacturing of finished-dose devices create capacity barriers that are hard to replicate quickly. This is backed by real spending: 2025 PP&E capital expenditure reached DKK 60.140 billion (Novo Nordisk Annual Report 2025, Financial performance). Capacity expansion itself is a way to raise the manufacturing moat.
  • Regulatory and patent barriers plus channels and physician habits: prescription drugs require clinical trials, registration, pharmacovigilance, and compliance systems, layered with physician prescribing pathways and patient titration habits. Switching costs are not zero.
  • The long-term structure of foundation control: Novo Holdings owns 28.05% of the capital and 77.28% of the votes, backed by the Novo Nordisk Foundation, giving the company a naturally long-term orientation.

  The moat is real and wide in the financial results: ROIC was 69.0%, 73.6%, 88.5%, and 63.9% in 2021–2024, and even after falling in 2025 it was still 39.3%. Such persistently high returns on capital are the financial fingerprint of a wide moat. The report's 4/5 moat score is reasonable.

  But the key part of the Baillie question is whether the moat will widen or narrow over the next three to five years. The honest answer is narrow. There are three pieces of evidence, all from current company disclosures:

  1. Profit power is being eroded by payers and competitors. Novo Nordisk's 2026 guidance explicitly cites lower realised prices, intensified competition, and loss of exclusivity for semaglutide in some international markets (Novo Nordisk Q1 2026 Form 6-K). If the moat is pricing power, part of it is being surrendered. Q1 adjusted sales were already -4% CER and adjusted operating profit -6% CER.

  2. Loss of exclusivity is structural and irreversible. The loss of exclusivity for semaglutide in some international markets means generics or biosimilars will eat into share. This is not a cyclical fluctuation but the normal form of a patent cliff, and the patent layer of the moat is melting as it expires.

  3. The rival is overtaking faster in dosage form and execution. Lilly's Q1 2026 revenue rose 56% year over year, and its oral GLP-1 Foundayo, orforglipron, has received FDA approval and launched (FDA approves Lilly's Foundayo). Competition has moved from product leadership to full-spectrum conflict across product, price, channel, and dosage form. The leadership-distance component of the moat is being compressed.

  It is also important to name the part of the moat that was never especially strong, without inflating the growth story: Novo Nordisk has no network effect and no self-reinforcing structure where more users make it harder to replace. Its data advantage lies in clinical evidence and physician education, not in a platform-style data barrier that directly locks in users. It is a high-barrier pharmaceutical moat, not a platform moat that deepens with use. Moats of this type are naturally more fragile than platform moats when facing patent and price cycles.

  Conclusion: the moat is still wide and real today, with manufacturing and brand as hard assets, but the trend has clearly shifted from only widening to stable with a narrowing bias. The report's 4/5 score, and its note that the trend has moved from widening to stable with a narrowing bias, is an honest and precise answer to this question.

  Jun 11, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  It has some DNA for reinvention, but that DNA has recently been tested by a loss of momentum. Novo Nordisk has historically completed the paradigm shift from insulin to GLP-1, proving that it can remake itself when core technology changes. Its attitude toward bad news is also relatively honest. But the 2025 CEO change shows that, in its most recent bout of competitive deceleration, the board judged the existing response insufficient.

  Start with the implied premise behind reinvention DNA. What Baillie Gifford is really asking is whether, if the core business is disrupted, this company can change the engine without changing the vehicle. Novo Nordisk has positive historical evidence. It was a century-old insulin leader, but it did not get trapped in insulin. Instead, it actively shifted its center of gravity to GLP-1, first in diabetes and then obesity, completing a self-disruption in product paradigm. The financial result of this shift was revenue rising from DKK 122.0 billion in 2019 to DKK 309.1 billion in 2025, a 6-year CAGR of about 16.8% (Novo Nordisk Annual Report 2025, Financial performance). So the claim that it can reinvent itself during a technology transition is not empty; it has done it once.

  It is now attempting a second reinvention: expanding from weekly injection to daily oral dosing. Oral Wegovy has launched and contributed DKK 2,256 million in Q1 2026 revenue (Novo Nordisk Q1 2026 Form 6-K). Together with DKK 29.973 billion of intangible-asset investment in 2025, mainly for business development including the Akero transaction, this shows that the company is actively positioning beyond the current product set. The reinvention actions are happening, though the results have not yet fully arrived, as discussed in the second-curve question.

  But this DNA has a real limit that must be stated honestly: Novo Nordisk's reinventions have historically been iterations within the metabolic/biologics arena where it is already strong, not leapfrogging transformations. It has no record like a platform company turning to an entirely new business after the core is completely disrupted. If the future disruption comes not from dosage form, oral dosing, but from a completely different weight-loss mechanism or delivery route that a rival captures first, whether Novo Nordisk can reinvent itself quickly remains an open question with no historical proof. That is also why its moat is judged to be a pharmaceutical moat, not a platform moat.

  Now look at how it treats mistakes and bad news. This is the more observable part of the question and a relative positive for Novo Nordisk:

  • It actively separates flattering and unflattering metrics in its financial reports. In Q1 2026, the company clearly distinguished reported sales, DKK 9.682 billion, lifted by a one-off 340B provision reversal, from adjusted figures, and acknowledged adjusted sales of -4% CER and adjusted operating profit of -6% CER (Novo Nordisk Q1 2026 Form 6-K). It did not use a one-off non-cash item to dress up the accounts as continued rapid growth, which the report rightly views positively.
  • It puts bad news directly into guidance. The 2026 guidance explicitly acknowledges lower realised prices, intensified competition, and loss of exclusivity for semaglutide in some markets, and even gives an adjusted sales range of -4% to -12%. That is putting bad news on the table rather than hiding it.
  • It acknowledges missed targets in the remuneration report. The report cites the company's remuneration report, which acknowledges that LTIP 2024 and LTIP 2025 tracking were below target. That is an honest disclosure of what was not achieved.

  The weightiest bad-news signal is that the company changed CEO in 2025. The report judges this as showing that the board was not satisfied with the company's loss of momentum. This cuts both ways. On the positive side, it shows that governance does not protect underperformance and will act to correct a slowdown; the self-correction mechanism works. On the other side, it also shows that when Lilly accelerated its attack in the prior round, the board judged the company's existing response not good enough. Whether the new CEO, Maziar Mike Doustdar, can deliver genuine reinvention is something to watch, not something that can be concluded today.

  The honest conclusion: Novo Nordisk has a real foundation for reinvention, shown by the successful insulin-to-GLP-1 transition, and it is relatively transparent about bad news, distinguishing reporting bases, embedding problems in guidance, admitting missed targets, and even changing the CEO. That is positive for a large pharmaceutical company. But its reinvention has been iteration within its own arena rather than cross-boundary rebuilding, and the most recent slowdown has already triggered a leadership change. The reinvention gene is present, but whether this round of reinvention succeeds remains an open question.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deeply aligned interests with the company? Is it willing to sacrifice current profit for the next five to ten years?6/10

  A

  The long-term view is institutionally strong. Interest alignment exists, but is not extremely strong. The company is sacrificing current profit for the long term, but through aggressive investment rather than restraint. Overall this is credible, while recent market trust needs rebuilding. Also, there is no founder at the helm, so the founder-deep-alignment element Baillie Gifford prizes most does not apply.

  First clarify the premise of this Baillie Gifford question. The ideal target is a founder-led company where the founder owns a large stake, thinks in decades, and is willing to trade current profit for long-term value. Novo Nordisk is a special case on that yardstick: its long-termism does not come from a founder, but from a foundation-controlled structure.

  Long-term view: institutionally strong, and this is Novo Nordisk's hardest governance strength. According to the governance disclosures cited in the report, Novo Holdings owns 28.05% of the capital and 77.28% of the voting rights, backed by the Novo Nordisk Foundation; ownership percentages should be checked against the latest 20-F governance section. This foundation-holding company-listed entity structure makes it naturally less hostage to quarterly earnings and short-term shareholders. It follows the Novo Nordisk Way over the long term and has a full board-committee structure. The report's judgment that governance is clearly long-term oriented is reasonable. It can withstand short-term pressure to make long-term investments better than most widely held large pharmaceutical companies.

  Interest alignment: present but not very strong, with two blemishes that should be stated honestly.

  • Management does hold shares and meets shareholding requirements. At the end of 2025, CEO Maziar Mike Doustdar held 107,569 shares, worth about DKK 35.00 million; CFO Karsten Munk Knudsen held 238,828 shares, worth about DKK 77.70 million (Novo Nordisk Annual Report 2025). That is skin in the game, but relative to compensation and company size, the intensity of alignment is moderate. It is far from a founder-level concentrated bet.
  • First blemish: the former CEO's departure compensation does not look good for minority shareholders. The report cites the remuneration report: Lars Fruergaard Jørgensen received DKK 22.20 million in 2025 service-period compensation, plus DKK 36.50 million of notice-period compensation, DKK 42.90 million of severance, and DKK 22.00 million of non-compete compensation. The report's phrasing, that this is not necessarily improper but does not look good for minority shareholders, is appropriate. A costly departure package after a slowdown and CEO change is a deduction for alignment.
  • Second blemish: the company itself admits long-term incentives missed target. The remuneration report acknowledges that LTIP 2024 and LTIP 2025 tracking were below target. That in turn shows incentives are tied to performance, which is honest, but it also shows management has not recently delivered target long-term value for shareholders.

  Is it willing to sacrifice current profit for the next five to ten years? Yes, but the method and cost matter. Novo Nordisk is giving a very clear answer here, perhaps too clear: it is sacrificing current free cash flow for long-term investment. In 2025, PP&E capital expenditure was DKK 60.140 billion and intangible-asset investment was DKK 29.973 billion, including Akero and other BD, pushing official free cash flow down to only DKK 28.295 billion (Novo Nordisk Annual Report 2025, Financial performance). The company even proactively changed its free-cash-flow definition in 2026 and acknowledged that the old definition was no longer suitable for representing true distributable cash. This shows that it is indeed sacrificing near-term cash for long-term capacity and pipeline, which is directionally consistent with what Baillie Gifford likes.

  But there is a necessary reservation about the rationality of capital allocation. The report points out that 2025 buybacks fell to only DKK 1.388 billion, far below DKK 20.181 billion in 2024. The buyback behavior does not clearly demonstrate the discipline to repurchase heavily when the stock is undervalued; the share price had fallen sharply from its 2024 high, theoretically a good moment for buybacks, yet the company reduced them. This separates sacrificing current profit for the long term from optimal capital allocation. It is willing to spend for the long term, on capacity and BD, but whether the spending direction maximizes intrinsic value per share remains uncertain. The report's 3.5/5 score for management and capital allocation, and its key assumption that management must refocus capital allocation over the next three years on intrinsic-value-per-share growth, are honest and necessary reservations.

  The honest conclusion: Novo Nordisk's long-term view is institutionally supported by the foundation structure, which is strong. It is willing to sacrifice current cash for the long term, and is doing so aggressively. But management's personal alignment is only moderate, with blemishes including high departure compensation, aggressive capacity expansion, weaker buyback discipline, and the 2025 CEO change. Market trust needs time to rebuild. This is not the Baillie archetype of a founder putting a large share of personal wealth on the line. It is a combination of institutional long-termism and moderate professional-manager alignment. The long-term orientation is credible, but not perfect.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?6/10

  A

  If Novo Nordisk disappeared tomorrow, patients would miss it a lot, but not in an irreplaceable way, because Lilly can already provide highly substitutable options. Its growth model is broadly sustainable and does not depend on harming society; in fact it improves public health. But it is highly exposed to the regulatory and social issue of drug affordability, which is the real weak point in its indispensability.

  This Baillie Gifford question has two implicit dimensions that should be answered separately: indispensability, meaning how much customers would miss it if it disappeared, and social/regulatory sustainability, meaning whether the growth model is healthy and sustainable.

  Dimension one: indispensability. It is high for patients, but discounted on whether only Novo can provide the answer.

  On the positive side, Novo Nordisk's products are deeply embedded in chronic-disease management for hundreds of millions of people. Diabetes and obesity are lifelong chronic diseases, with long-term and recurring demand. Novo Nordisk is the global branded-volume share leader, with about 59.6% branded volume market share in 2025 (Novo Nordisk Annual Report 2025, Financial performance), and Wegovy has launched in more than 55 countries. For patients using Ozempic/Wegovy for glucose control and weight loss, its disappearance would cause real treatment disruption and health loss. The degree of being missed would be high.

  But Baillie Gifford is really asking about irreplaceability, and here the answer must be discounted. GLP-1 is already a market with a strong second supplier. Lilly's Mounjaro/Zepbound are highly substitutable treatments. In Q1 2026, the two generated combined revenue of about USD 12.82 billion, while Lilly's total revenue rose 56% year over year (Lilly Q1 2026 press release), and Lilly's oral GLP-1 Foundayo, orforglipron, has been approved by the FDA and launched (FDA approves Lilly's Foundayo). In other words, if Novo Nordisk disappeared tomorrow, patients would suffer and be forced to switch, but clinically they would have somewhere to go. That is different from true indispensability where no equivalent alternative exists. The report repeatedly stresses that once a blockbuster new mechanism or better dosage form appears, share can switch very quickly. That is exactly this substitutability.

  Dimension two: social and regulatory sustainability. The growth model is healthy, but deeply tied to the powder keg of drug affordability.

  The good side: Novo Nordisk's growth does not rely on harming society. At its core, it improves public health. It treats global epidemics as defined by WHO: in 2022 about 1 in 8 people globally were living with obesity, and adult obesity had more than doubled since 1990 (WHO Obesity and overweight); IDF estimates 589 million adults with diabetes globally in 2024, rising to 853 million by 2050 (IDF Diabetes Atlas 2025). Turning these populations from having no effective drug treatment into treatable patients creates positive social value. It does not have the ethical flaw of relying on addiction or harming users. In this respect, it withstands ESG scrutiny better than many consumer or platform companies.

  But the weak point is also here: its profits are directly tied to drug prices, and drug pricing is a highly politicized and regulated social issue. The report repeatedly cites the company's 2026 guidance references to the gross-to-net system, Most Favoured Nations drug-pricing policy, and the 340B program. These are all tools through which regulators directly compress pricing power, and the company has already written lower realised prices into guidance. There is also gray-area disruption: the report notes that although the FDA has announced that the semaglutide injection shortage has been resolved and routine compounding should be limited, lower-priced compounded oral or online channels may still disturb price perception. In short, the more it is seen as a high-priced life-saving drug, the more payers, governments, and the public will press for lower prices. The growth model itself is sustainable, but the profit margin of that growth is highly exposed to society's tug-of-war over drug affordability.

  The honest conclusion: patients would miss Novo Nordisk's products a lot, but the products are not irreplaceable, with Lilly as a strong Plan B. The growth model is healthy and socially positive, because it treats global epidemics, and does not depend on harming society. But the company's lifeline is in a field where regulators and the public are continuously watching and pressing prices down. Society needs its drugs and also wants them cheaper. That tension is the most real crack between its indispensability and profit sustainability. This also matches the report's decision to list U.S. gross-to-net, net price, and 340B/MFN policy impact as the primary tracking indicator.

  Jun 11, 2026
• QWhat are the unit economics of this business, in gross margin and incremental returns? Do they improve or deteriorate as scale increases? Where does the money it earns go?8/10

  A

  The unit economics are top-tier: 81% gross margin, 41% operating margin, and historical ROIC of 60%–88%. As scale grew, margins stayed stable rather than declining. But two marginal turning points must be stated honestly: gross margin fell from about 85% in 2025 to 81%, incremental return on capital, ROIC, has fallen from a peak of 88.5% to 39.3%, and the money is going mainly into capacity expansion and business development rather than buybacks.

  Start with the absolute level, Novo Nordisk's strongest point. In 2025, with all figures checked against Novo Nordisk Annual Report 2025, Financial performance:

  • Gross margin 81.0%, versus 84.7% in 2024. This is pharmaceutical-grade high gross margin, meaning that most of each additional box sold becomes marginal contribution.
  • Operating margin 41.3%, DKK 127,658m / 309,064m.
  • Net margin 33.1%, with net profit of DKK 102,434m.

  This margin structure has been extremely stable as scale increased: the report gives 2021–2025 operating margin as consistently around 41%–44% and net margin around 31%–36%. In other words, the unit economics of this business did not deteriorate during the past volume expansion. That is a core feature of a high-quality business, and the report's 4.5/5 business-quality score is supported by data.

  Now look at incremental returns, the soul of this Baillie question: how much profit can an additional unit of capital earn? Novo Nordisk's historical answer is striking. The report gives ROIC of 69.0%, 73.6%, 88.5%, and 63.9% in 2021–2024. Returns at that level mean the business was historically a compounding machine.

  But the honest judgment has to focus on the margin of change. Three inflection points cannot be avoided:

  1. Gross margin has visibly moved lower: from about 84.7% to 81.0%, a decline of about 3.7 percentage points. Combined with the company's active price-for-volume trade, lower realised prices and lower unit prices for oral dosage forms, the price leg of the unit-economics structure is loosening. Q1 2026 adjusted sales were already -4% CER and adjusted operating profit -6% CER (Novo Nordisk Q1 2026 Form 6-K), showing that margin pressure is current, not theoretical.

  2. Incremental return on capital has clearly fallen: ROIC dropped from the 2023 peak of 88.5% to 39.3% in 2025. 39.3% is still excellent, but a move from 88.5% to 39.3% is a halving-scale decline. The report interprets this as return on capital falling from a peak after heavy capital expansion, and lists declining capital returns as one path to permanent loss. That is an honest acknowledgment that incremental returns get worse as scale expands. In other words, the business is converging from extremely high incremental returns toward excellent but more normal large-pharma incremental returns.

  3. Where the money goes is the most important follow-up in unit economics. The answer is heavy investment and light buybacks: in 2025, PP&E capital expenditure was DKK 60.140 billion and intangible-asset investment was DKK 29.973 billion, including Akero and other BD, pushing official free cash flow down to only DKK 28.295 billion. Meanwhile, share buybacks plunged from DKK 20.181 billion in 2024 to DKK 1.388 billion in 2025 (Novo Nordisk Annual Report 2025, Financial performance). The money is going mainly into capacity and pipeline. That can be good in itself, building the base for future growth, but the report sharply notes that whether these capacity-expansion outlays turn into future cash flow, and whether they are better than buybacks when the share price is depressed, remains an open question. This is also why accounting profit, DKK 102.4 billion of net income, diverged materially from cash truly attributable to shareholders, with the report conservatively estimating owner earnings at about DKK 60.0 billion, during the 2024–2026 window.

  The honest conclusion: Novo Nordisk's unit economics are textbook excellent, with high gross margin, high margins, and historically very high ROIC, and margins stayed stable as scale grew. That is the core reason it deserves the high-quality growth label. But at the margin, gross margin is moving lower, incremental return on capital has halved from its peak, and the company is currently in a phase where heavy investment depresses free cash flow. Money is going into capacity and BD rather than buybacks. Its unit economics remain top-tier, but the slope of scale making the business more profitable is flattening. That is the internal logic behind the report's combination of a high business-quality score and a judgment that valuation is not cheap.

  Jun 11, 2026
• QWhat conditions must all hold for it to rise fivefold over ten years? Are those conditions realistic? What expectations are embedded in today's share price?3/10

  A

  A fivefold rise over ten years would require a fairly demanding set of conditions to hold simultaneously. Realism is currently low. This is a fivefold-over-ten-years question, not a mistaken reference to a higher multiple; in the Baillie framework, fivefold is already a high bar. Today's share price of about USD 42.81 does not embed a high-growth expectation. It embeds expectations for a high-quality but maturing pharmaceutical company with slowing growth and pressured pricing power. The market has already squeezed out most of the optimism.

  First anchor today's price facts, using the same price anchor throughout this piece: as of the 2026-06-10 close, NVO ADR was about USD 42.81, with market capitalization around USD 194.0 billion, trailing PE about 10.3x, forward PE about 13.9x, analyst consensus at Buy, and an average price target around USD 47 (stockanalysis.com NVO). This is another roughly 4% lower than the report snapshot, about USD 44.74 on 2026-05-15, directionally confirming the report's view that the price had not reached an ideal zone and sentiment was weak.

  What conditions must all hold for a fivefold rise over ten years? Moving from about USD 42.81 to about USD 214, with market capitalization approaching USD 1 trillion, means almost all of the following must happen:

  1. Revenue and profit return to high growth and sustain it for ten years: the report's historical measure shows 2019–2025 revenue CAGR of about 16.8%, but current 2026 full-year guidance is adjusted sales of -4% to -12%, CER (Novo Nordisk Q1 2026 Form 6-K). A fivefold outcome requires the company to reverse powerfully from negative-growth guidance and then compound at high double-digit rates for ten consecutive years. This is the first and hardest gate.
  2. Defend share and avoid continued erosion by Lilly: weekly injectable GLP-1 share must not fall below the current roughly 55% level and must stabilize; the report explicitly lists a clear break below 55% share with continuing deterioration as a falsification condition. Yet Lilly's Q1 2026 revenue was +56%, and oral Foundayo has launched (Lilly Q1 2026 press release), so defending share is not easy.
  3. The price system stabilizes and margins are not crushed: U.S. gross-to-net, MFN, 340B, and other price-pressure factors must not permanently pull net margin from 33% toward ordinary large-pharma levels. Yet the company has already written lower realised prices into guidance.
  4. Cash flow repairs strongly: after the 2026–2028 capacity-expansion peak, PP&E capital expenditure must fall from the DKK 60.0 billion range, allowing owner earnings to rise materially from the report's conservative estimate of about DKK 60.0 billion (Novo Nordisk Annual Report 2025, Financial performance).
  5. The second and third curves deliver: oral Wegovy must generate reasonable profit despite lower unit price, and the next-generation obesity pipeline/BD must genuinely take over rather than merely draw on the existing product franchise.
  6. The valuation multiple expands as well: even if profit rises severalfold, the market also needs to award a higher multiple again. Today's forward PE of only about 13.9x leaves room for multiple expansion, but only if the narrative turns optimistic again.

  Each condition on its own is not absurd, but requiring all of them at once is extremely demanding, especially because conditions 1, 2, and 3 conflict with one another: the company must grow quickly, defend share, and avoid doing so by cutting price. The report's own three-scenario owner-earnings DCF gives an optimistic intrinsic value of only USD 56–67 per ADR, corresponding to an optimistic expected annual return of about 12%–15% a year. Even in the most optimistic case, that is about 3–4x over ten years, not fivefold. The honest conclusion is that a fivefold ten-year outcome is a low-probability tail scenario requiring a string of difficult conditions to light up simultaneously, not the base case.

  What expectations are embedded in today's share price? This is the most important sub-question, and the answer is the counterintuitive bright spot: at about USD 42.81, trailing PE about 10.3x and forward PE about 13.9x, the pricing implies that the market no longer believes in high growth. The report is perceptive here. A static PE around 12.5x can make many people think it looks cheap at first glance, but using owner earnings, which better approximates cash distributable to shareholders, the current price is about 20–23x conservative owner earnings, with an owner-earnings yield of only about 4.7%. Compared with the 10-year U.S. Treasury yield of about 4.55% (U.S. Treasury yields, 2026-06-10), that provides little comfortable risk compensation. In other words, the low PE is not a hidden bargain the market has missed. It is the market pricing in slower growth, pressured pricing power, and cash flow suppressed by capacity expansion. Analyst consensus target price of about USD 47, only about 10% upside, also confirms that the market currently sees it as reasonably priced, not deeply discounted below conservative value.

  The honest conclusion: a fivefold ten-year outcome requires 6 difficult conditions to hold simultaneously, and realism is low; even the report's most optimistic scenario is only about 3–4x over ten years. Today's price of about USD 42.81 does not embed a growth premium. It embeds restrained expectations for a high-quality mature pharmaceutical company with slowing growth and price pressure. The market is not overly optimistic, but it also has not provided a Baillie-style entry point with excellent odds. This fully matches the report's final judgment: reasonable but not cheap, with the margin of safety failing.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Is it because it does not understand, does not respect it, or cannot look far enough ahead? What will be the narrative inflection point?3/10

  A

  The premise embedded in this Baillie question needs correction. It usually assumes that the market is underestimating a good company and that there is an insight gap to capture. Novo Nordisk is the opposite case: the market has already recognized its problems fully, perhaps even pessimistically. This is not about failing to understand, respect, or look far enough ahead. It is about seeing the issues clearly and assigning a discount. The narrative inflection point therefore runs in the opposite direction: not when the market discovers how good it is, but whether cash flow and share prove the bad news has been over-priced.

  Use price facts first to show that the market has already realized it. Novo Nordisk ADR has fallen from a historical high of about USD 137 in June 2024 to about USD 42.81 at the 2026-06-10 close, with the 52-week range reaching as low as about USD 35 (stockanalysis.com NVO), a drawdown of about 70% from the peak. A company the market does not understand or respect would not be priced like this. This is the result after the market has priced in slowing growth, Lilly overtaking, and pressured pricing power. The report says this directly: the market has shifted from past extreme optimism to a state that is more skeptical of Novo and more favorable to Lilly. So the honest starting point for this question is that the insight gap has largely been consumed, not hidden and waiting to be dug out.

  Testing the three possibilities, not understanding, not respecting, and not looking far enough, shows that none fits very well:

  • It is not a case of not understanding: GLP-1 and obesity have been among the world's most thoroughly researched pharmaceutical themes since 2023. Many sell-side analysts cover it, analyst consensus is Buy, and the average target price is about USD 47 (stockanalysis.com NVO). The market understands the business well.
  • It is not a case of not respecting it: Novo Nordisk is the global branded-volume share leader, about 59.6% in 2025 (Novo Nordisk Annual Report 2025, Financial performance). It has never been treated as an insignificant small company. It is being priced precisely as a former king now under pressure.
  • It is closest to not looking far enough, but in the opposite direction: if there is a cognitive bias, the market may be over-extrapolating recent negative growth by linearly extending 2026 adjusted sales guidance of -4% to -12% (Novo Nordisk Q1 2026 Form 6-K) into long-term stagnation, while underestimating the possibility of cash-flow recovery after the capacity-expansion peak. This is the potential positive insight gap implied by the report's owner-earnings framing: the company looks pressured, but the cash-flow definition may reveal more nuance. Still, this is a case of possible excessive pessimism, not the Baillie-style assumption that the market has not discovered how good the company is.

  It is also necessary to admit that the current discount may be rational pricing rather than mispricing. The report calculates that on an owner-earnings basis, the current price is about 20–23x conservative owner earnings, with an owner-earnings yield of only about 4.7%. Compared with the 10-year U.S. Treasury yield of about 4.55% (U.S. Treasury yields, 2026-06-10), there is almost no excess compensation. In other words, the apparently cheap static PE of about 10–13x is precisely the market's rational response to cash return and a still-heavy reinvestment burden. That is not the market's error; it is the market incorporating the real cash-flow measure into price. The report's valuation judgment, reasonable but not cheap and failing the margin of safety, is based on this point.

  What will be the narrative inflection point? This is the sub-question the prompt asks to add. The inflection point is not the market suddenly discovering the company's quality. It is the fundamentals providing directional evidence that forces one of two outcomes: the bad news was over-priced, or the bad news was only beginning.

  • Upside inflection signals: after the capacity-expansion peak, PP&E capital expenditure falls clearly from the DKK 60.0 billion range and free cash flow/owner earnings recover for several consecutive quarters; weekly injectable GLP-1 share holds around 55% and stops deteriorating; oral Wegovy scales internationally with a gross-margin structure better than expected; next-generation pipeline/BD delivers high returns. Confirmation of any of these would shift the narrative from mature low-growth pharma back toward high-quality growth, triggering multiple re-rating.
  • Downside inflection signals, which must be stated just as honestly: Lilly continues taking share and Novo has no product response; the price system worsens further and permanently lowers net margin; capital expenditure stays high while cash flow fails to recover; major rebate or channel-accounting items again create large reporting disruption. The report lists these as falsification conditions and triggers for reassessment. Confirmation of any one would validate structural deterioration in the moat and capital-allocation returns.

  The honest conclusion: Novo Nordisk is not a cheap good company the market has not noticed. It is a high-quality but pressured company the market has already recognized and discounted. The insight gap has largely been priced in, and the current discount is more likely rational than mistaken. The real question is not waiting for the market to discover it, but waiting for fundamentals in cash flow and share to prove whether today's pessimism is excessive or appropriate. Until that evidence appears, the report's placement of Novo Nordisk at the front of the Watch list, rather than a Buy now, is the most restrained and honest answer to this question.

  Jun 11, 2026